Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:9UA Stock Latest News

The FlyNervGen Pharma doses first participant in RESTORE trial2w agoNGEN

Company AnnouncementsNervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results1M ago6K NGEN
The FlyNervGen Pharma to restate previously filed financial statements1M agoNGEN
Company AnnouncementsNervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation1M ago6K NGEN
The FlyNervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year2M agoNGEN

NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position

Company AnnouncementsNervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position2M ago6K NGEN

The FlyNervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright3M agoNGEN

The FlyNervGen Pharma initiated with an Outperform at Leerink3M agoNGEN

Company AnnouncementsNervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners4M ago6K NGEN
The FlyNervGen Pharma initiated with a Buy at TD Cowen4M agoNGEN
Company AnnouncementsNervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program5M ago6K NGEN
Company AnnouncementsNervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 35M ago6K NGEN

NervGen Pharma files $250M mixed securities shelf

The FlyNervGen Pharma files $250M mixed securities shelf5M agoNGEN

The FlyNervGen Pharma announces biomechanical gait analyses on recovery with NVG-2915M agoNGEN

Company AnnouncementsNervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development5M ago6K NGEN

The FlyNervGen Pharma 24M share Spot Secondary priced at $2.505M agoNGEN
The FlyNervGen Pharma secondary being re-offered at $2.50 per share5M agoNGEN
The FlyNervGen Pharma announces common share offering, no amount given5M agoNGEN
Company AnnouncementsNervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows5M ago6K NGEN

NervGen Pharma reports Q1 EPS (2c), consensus (7c)

The FlyNervGen Pharma reports Q1 EPS (2c), consensus (7c)5M agoNGEN

Company AnnouncementsNervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing5M ago6K NGEN

Company AnnouncementsNervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan6M ago6K NGEN